KaloBios Pharmaceuticals, Inc.' KB001 Demonstrates Safety, Potential as New Approach to Preventing Pseudomonas Ventilator Associated Pneumonia

Published: Jun 25, 2012

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Phase 2a trial results with KB001 suggest the recombinant, human PEGylated monoclonal antibody fragment, under development by KaloBios Pharmaceuticals, Inc. and Sanofi Pasteur, offers potential as an alternative to antibiotics for preventing or reducing pneumonias in mechanically ventilated intensive care unit (ICU) patients heavily colonized with Pseudomonas aeruginosa (Pa). Results of the Phase 2a study, sponsored in its entirety by KaloBios and conducted at 10 ICUs across France, have been published online and will appear in the August issue of Critical Care Medicine.

Back to news